AP Drug Control Launches Mega GMP Inspection Across 400 Pharma Firms

Published On 2025-10-26 06:45 GMT | Update On 2025-10-26 06:45 GMT

Amravati: The Drugs Control Department of Andhra Pradesh has initiated a massive inspection drive across the state, targeting nearly 400 pharmaceutical companies to ensure compliance with the revised Schedule M of the Drugs and Cosmetics Act, 1940, which came into effect on January 1, 2025.

According to officials, inspection teams comprising drug inspectors and senior officers—including Assistant Directors and Deputy Directors—are visiting pharmaceutical units engaged in manufacturing bulk drugs and formulations. The focus is primarily on firms with an annual turnover below ₹250 crore, those that have not been inspected in the past year, and those that failed to apply for exemption from the new Schedule M norms by December 31, 2024.

Also Read: Luxury Cars for Employees: This Pharma Firm's Diwali Giveaway Goes Viral

The inspections are aimed at verifying adherence to updated Good Manufacturing Practices (GMP). Officials are assessing manufacturing facilities for upgraded processes, installation of advanced machinery, use of quality raw materials, proper record maintenance, and end-to-end monitoring of procurement, production, and product release. Each inspection is expected to take between one and two days per unit, depending on the scale of operations.

Authorities stated that the state-wide inspection exercise is expected to be completed within a month. In case of any deviations or non-compliance, firms will be issued show-cause notices and further action will be taken based on their responses. So far, officials have reported no major violations, confirming that no quality issues have been detected in cough syrup production and that banned formulations are not being circulated in the state, reports the Deccan Chronicle.

Also Read: Maharashtra FDA Launches Special Drive to Inspect Liquid Oral Formulations

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Parthika Patel

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AP Drug Control Launches Mega GMP Inspection Across 400 Pharma Firms

Similar News

Lilly to buy Adverum Biotechnologies

Dr Reddy's Labs assigns additional responsibilities of CHRO office to Sanjay Sharma

DoP Invites Retired Central Govt Officers for Consultant Roles, Apply by Oct 31

Modi Mundipharma Gets SEC Approval to Study Cingal, a Hyaluronic Acid-Steroid Device for Osteoarthritis Knee Pain

Syngene International plans to add bioconjugation suite for end-to-end Antibody-Drug conjugates development

CDSCO Panel Rejects Troikaa Pharma's High-Strength Paracetamol Injection Citing Safety Concerns

CDSCO Flags Besto-Cof Cough Syrup as Spurious, Raipur Drug Lab Claims Batch Not Made by Listed Firm